Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne F Jones

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
The Oncologist|August 28, 2010
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignanciesHoward A Burris, Jeffrey R Infante, Roxanne C Jewell, et al.
European Journal of Cancer (Oxford, England : 1990)|January 9, 2013
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancerJeffrey R Infante, Johanna C Bendell, Laura Williams Goff, et al.
Cancer Investigation|March 10, 2010
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancerHoward A Burris, Suzanne F Jones, Dianna Shipley, et al.
Cancer Investigation|April 28, 2012
Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumorsSuzanne F Jones, Jeffrey R Infante, David R Spigel, et al.
Investigational New Drugs|October 23, 2014
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancerJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Investigational New Drugs|March 26, 2013
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumorsShubham Pant, Howard A Burris, Kathleen Moore, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2016
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelleHoward A Burris, Jeffrey R Infante, F Anthony Greco, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C Bendell, David S Hong, Howard A Burris, et al.
The Oncologist|March 11, 2022
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World SettingsEmma G Sturgill, Amanda Misch, Carissa C Jones, et al.
Investigational New Drugs|January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsHoward A Burris, Suzanne F Jones, Daphne D Williams, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
The Oncologist|August 28, 2010
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignanciesHoward A Burris, Jeffrey R Infante, Roxanne C Jewell, et al.
European Journal of Cancer (Oxford, England : 1990)|January 9, 2013
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancerJeffrey R Infante, Johanna C Bendell, Laura Williams Goff, et al.
Cancer Investigation|March 10, 2010
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancerHoward A Burris, Suzanne F Jones, Dianna Shipley, et al.
Cancer Investigation|April 28, 2012
Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumorsSuzanne F Jones, Jeffrey R Infante, David R Spigel, et al.
Investigational New Drugs|October 23, 2014
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancerJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Investigational New Drugs|March 26, 2013
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumorsShubham Pant, Howard A Burris, Kathleen Moore, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2016
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelleHoward A Burris, Jeffrey R Infante, F Anthony Greco, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C Bendell, David S Hong, Howard A Burris, et al.
The Oncologist|March 11, 2022
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World SettingsEmma G Sturgill, Amanda Misch, Carissa C Jones, et al.
Investigational New Drugs|January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsHoward A Burris, Suzanne F Jones, Daphne D Williams, et al.
Pageof 7